Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a statistically significant response rate in systemic lupus erythematosus (SLE) patients over standard care alone, failing the primary goal of a Phase 3 clinical trial, according to top-line results. Although not statistically significant, the investigational treatment did, however, show…
News
The Lupus Research Alliance recently announced the nine winners of its Novel Research Grants, to support innovative research on lupus. The grants support research into the complexity of lupus from different perspectives. Among the nine winners, studies vary from testing new and existing therapies, to exploring paths for…
Treatment with 150 mg atacicept significantly improves outcomes in systemic lupus erythematosus (SLE) patients with high disease activity, data from a Phase 2b clinical trial show. The results of the trial were presented recently at the 2018 SLEuro Annual Meeting in Dusseldorf, Germany in a poster titled “SRI response,…
A new test looking at the presence of 26 autoantibodies — antibodies targeting a person’s own healthy proteins — is better at diagnosing systemic lupus erythematosus (SLE) and predicting its course than conventional ones, a study shows. The test was developed using several newly identified autoantibodies for SLE, and groups…
A Phase 2 clinical trial testing a Corbus Pharmaceuticals’ synthetic cannabinoid derivative – lenabasum (JBT-101) – for lupus patients is underway. The therapy has no psychotropic properties and is intended to treat joint inflammation associated with lupus. If proven effective, it may offer patients a…
Harmless bacteria that live in the skin, mouth and gut may trigger autoimmunity in people who are genetically disposed to it, according to a study with lupus implications. This means that targeting what scientists call commensal bacteria could be a way to development treatments for lupus and other autoimmune diseases,…
Treatment with atacicept — a protein that targets the immune system — significantly reduced disease flares in patients with systemic lupus erythematosus (SLE), data from EMD Serono‘s Phase 2 trial shows. The study, “Reduction of systemic lupus flares by atacicept in a randomized, placebo- controlled,…
Zhijian “James” Chen, PhD recently was awarded the 2018 Lurie Prize in Biomedical Sciences by the Foundation for the National Institutes of Health (FNIH) for his discovery of how DNA stimulates immune responses, potentially causing autoimmune diseases like lupus. The Lurie Prize in Biomedical Sciences will be presented to…
Top-line results of ImmuPharma’s Phase 3 clinical trial testing Lupuzor (rigerimod) as a systemic lupus erythematosus (SLE) treatment are expected by mid-April, according to the company. ImmuPharma also announced that database lock of the trial is expected by April 6. This milestone prevents unauthorized or unintended alterations to…
Suppressing the key inflammatory protein iRhom2 reduced inflammation and prevented kidney scarring in mice susceptible to developing lupus, a study suggests. This approach could be the basis of new treatments for kidney damage in patients with lupus and other autoimmune diseases, researchers believe. The study, “iRhom2 promotes…
Recent Posts
- Noninvasive markers track lupus disease activity, kidney damage
- With lupus, I reframe my work life around small, creative endeavors
- I’m creating a personal curriculum specifically tailored to life with lupus
- Caught without my helpful spend-a-night bag
- AMETHYST trial of litifilimab making “strong progress,” Biogen says